Skip to main content
Premium Trial:

Request an Annual Quote

PGDx, Qiagen Partner on Clinical Decision Support for Molecular Cancer Testing

NEW YORK – Personal Genome Diagnostics (PGDx) said on Wednesday that it is partnering with Qiagen to provide clinical decision support to users of its cancer genomic profiling tests.

Under the non-exclusive agreement, laboratories that purchase PGDx Elio oncology products will have an option to receive standardized reporting from Qiagen that is informed by professional guidelines to facilitate case review. In addition, laboratories will receive access to Qiagen's QCI Interpret One for rapid, evidence-based variant interpretation and reporting for next-generation sequencing (NGS) tests.

PGDx Elio Tissue Complete is a US Food and Drug Administration-cleared genomic profiling kit used to identify tumor alterations and inform treatment decisions for patients with advanced solid tumors. As a kitted test, Elio Tissue Complete can be performed by laboratories anywhere, and by pairing the kits with automated data-analysis and interpretation support, the companies hope to spur more widespread adoption of precision oncology testing.

"PGDx Elio Tissue Complete is a first-of-its-kind FDA-cleared kit to enable any molecular lab to perform comprehensive tumor profiling," PGDx CEO Megan Bailey said in a statement. "It is important for our customers to be able to stay up to date with clinical guidelines and evidence supporting variant interpretation to maximize the value of NGS data in improving clinical care. We've built the PGDx Elio software to deliver robust, high-quality variant calls. The addition of Qiagen clinical decision support software … provides labs an option for a comprehensive solution that will enable more informed treatment decisions for clinicians and patients."

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.